Drug profile · INN
diclofenac epolamine
LICART
diclofenac epolamine (LICART) is a cyclooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — diclofenac epolamine
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
diclofenac epolamine (LICART) is a cyclooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is diclofenac epolamine?
diclofenac epolamine (LICART) is a cyclooxygenase inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for diclofenac epolamine?
LICART is a marketed brand name for diclofenac epolamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diclofenac epolamine?
diclofenac epolamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.